Please login to the form below

Not currently logged in
Email:
Password:

liso-cel

This page shows the latest liso-cel news and features for those working in and with pharma, biotech and healthcare.

FDA approves BMS’ blood cancer CAR T therapy after delay

FDA approves BMS’ blood cancer CAR T therapy after delay

The US Food and Drug Administration (FDA) has finally approved Bristol Myers Squibb’s (BMS) CAR T-cell therapy Breyanzi, previously known as liso-cel, after delaying the decision in November

Latest news

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    11. Liso-cel for large B-cell lymphoma is being developed by Bristol-Myers Squibb to treat large B-cell lymphomas, and a filing in the third-line setting is being ... Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of

  • Deal Watch January 2018

    Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017 (liso-cel), CD19-directed CAR-T in pivotal trials for DLBCL.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...